BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Jefferies London Healthcare Conference 2025 Transcript

Core Insights - BioCryst is experiencing significant revenue growth from its product ORLADEYO, with current revenues between $590 million and $600 million, projected to peak at $1 billion [3] - The company has a strong patent protection for ORLADEYO extending to 2040, which supports its growth trajectory [3] - BioCryst has a pipeline that includes two clinical candidates: 17725 for Netherton syndrome and avoralstat for DME [3] - The company is in a favorable financial position, having proposed an acquisition of Astria [4]